Bafna Pharmaceuticals Ltd (BAFNAPH) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Bafna Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
We herewith enclose the Voting Results of the 31st Annual General Meeting of the Company held on September 11, 2026 along with the Scrutinizer Report.
Annual General Meeting · 11 Sept 2026, 11:44 pm
We herewith enclose the Outcome / Proceedings of the 31st Annual General Meeting of the Company held on September 11, 2026.
Annual General Meeting · 11 Sept 2026, 8:33 pm
We herewith enclose the Notice of 31st Annual General Meeting of the Company scheduled to be held on Friday, September 11, 2026 at 10.00 A.M along with the Annual Report of the Company ....
Annual General Meeting · 20 Aug 2026, 2:34 am
We herewith enclose the Annual Report of the Company for the F.Y 2025-2026.
Others (Uncategorized) · 20 Aug 2026, 2:29 am
We hereby inform that the 31st Annual General Meeting (AGM) of the Company is scheduled to be held on Friday, September 11, 2026 at 10.00 A.M through Video Conferencing (VC) / Other Audio ....
Annual General Meeting · 13 Aug 2026, 11:08 pm
We herewith enclose the Unaudited Financial Results for the Quarter ended June 30, 2026 as approved by the Board of Directors in its meeting held on August 11, 2026.
Financial Result · 11 Aug 2026, 11:39 pm
Bafna Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakhs) ■ Revenue: 2,658 (-23.2% YoY | -37.1% QoQ) ■ EBITDA: 88.2 (-82.6% YoY | -75.1% QoQ) ■ EBITDA Margin (%): 3.3 (-1132 bps YoY | -508 bps QoQ) ■ PAT: 7.5 (-97.8% YoY | -97.3% QoQ) ■ EPS (INR): 0.03 (-97.9% YoY | -97.4% QoQ)
We hereby inform you that the Board of Directors in their meeting held on August 11, 2026 inter-alia considered and approved i) Unaudited Financial Results of the Company for the Quarter ....
Outcome · 11 Aug 2026, 11:20 pm
Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve the Un-Audited Financial ....
Intimation · 11 Aug 2026, 5:30 am
Bafna Pharma Board Meeting on Aug 11, '26 for Q1FY27 Results Bafna Pharmaceuticals has scheduled a Board of Directors meeting on Aug 11, '26 to consider and approve the un-audited financial results for the quarter ending Jun 30, '26. In connection with this, the trading window for designated persons will remain closed from Jul 01, '26 to Aug 13, '26, inclusive.
Intimation for retirement of Mr. Navin Kumar (DIN: 08778662) as an Independent Director of the Company upon completion of his first term, with effect from close of business hours on June 22, 2026.
Change in Management · 22 Jun 2026, 10:10 pm
Bafna Pharma Announces Independent Director Retirement and Committee Changes Mr. Navin Kumar (DIN: 08778662) will retire as an Independent Director of Bafna Pharmaceuticals effective 22 Jun'26, upon completing his first term. He will also cease to be Chairman of the Audit and the Nomination & Remuneration Committees. Consequently, effective 23 Jun'26, both committees have been reconstituted. Mr. Palamadai Krishnan Sundaresan has been appointed as the new Chairman for the Audit Committee and the Nomination & Remuneration Committee. The company confirms continued compliance with all applicable laws following these changes.
Intimation for retirement of Mr. Navin Kumar (DIN: 08778662) as an Independent Director of the Company upon completion of his first term, with effect from close of business hours on June 22, 2026.
Change in Management · 22 Jun 2026, 10:05 pm
Bafna Pharma Announces Independent Director Retirement and Committee Changes Mr. Navin Kumar (DIN: 08778662) will retire as an Independent Director from Bafna Pharma on 22 Jun'26 upon completing his first term. He will also cease to be Chairman of the Audit and the Nomination & Remuneration Committees. Consequently, from 23 Jun'26, both committees will be reconstituted and chaired by Mr. Palamadai Krishnan Sundaresan. The other committee members are Mrs. Ravichandran Chitra, Mr. Upendar Mekala Reddy (Audit), and Mrs. Akila Chintalapati Raju (Nomination & Remuneration). The company confirms continued compliance with all applicable laws.
We herewith enclose the Audited Financial Results of the Company along with the Statutory Auditor''s Report for the Quarter and Year ended March 31, 2026, as approved by the Board of Directors ....
Financial Result · 30 May 2026, 12:24 am
Bafna Pharma Q4FY26 PAT Soars 109.7% YoY on Strong Revenue Growth Bafna Pharmaceuticals reported robust Q4FY26 results with a Profit After Tax of ₹274.91 lakhs, a 109.7% YoY increase. Revenue from operations grew 8.1% YoY to ₹4,223.93 lakhs. For the full year FY26, PAT surged 167.3% YoY to ₹1,109.98 lakhs, while revenue rose 3.3% YoY to ₹15,061.74 lakhs. The Board approved the audited financials for the quarter and year ended 31 Mar'26, accompanied by an unmodified audit opinion. Basic EPS for FY26 stood at ₹4.69, up from ₹1.76 in FY25.
We hereby inform you that the Board of Directors in their meeting held on May 29, 2026 inter-alia considered and approved the Audited Financial Results of the Company along with the Auditor's ....
Outcome · 30 May 2026, 12:09 am
Bafna Pharmaceuticals Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 4,224 (+8.1% YoY | +10.3% QoQ) ■ EBITDA: 355 (+14.0% YoY | +16.3% QoQ) ■ EBITDA Margin (%): 8.4 (+43 bps YoY | +43 bps QoQ) ■ PAT: 275 (+109.7% YoY | +49.7% QoQ) ■ EPS (INR): 1.16 (+110.9% YoY | +48.7% QoQ)
Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the Audited Financial ....
Intimation · 29 May 2026, 5:30 am
Bafna Pharma Sets Board Meeting for Q4 & FY26 Results Bafna Pharmaceuticals will hold a Board of Directors meeting on 29th May'26 to consider and approve the audited financial results for the quarter and year ended 31st Mar'26. Consequently, the trading window for designated persons is closed from 01st Apr'26 to 31st May'26, inclusive. This meeting is a key event for the company's financial reporting and stock performance evaluation.
We hereby submit our response to the Clarification sought by the Stock Exchange regarding the movement in the Share Price of the Company.
Others (Uncategorized) · 15 Apr 2026, 4:18 pm
Bafna Pharma Clarifies Share Price Movement, Cites Market Factors On Apr 15, '26, Bafna Pharmaceuticals responded to an exchange query regarding its significant share price movement. The company stated it is not aware of any withheld information or event that could have caused the price change. Management attributed the stock's movement to general market conditions and investor sentiment, asserting they have no connection with or control over the price action. Bafna confirmed its ongoing compliance with all SEBI disclosure requirements.
The Exchange has sought clarification from Bafna Pharmaceuticals Ltd on April 13, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 14 Apr 2026, 1:03 am
The Board of Directors of the Company in the Meeting held on March 27, 2026 has inter-alia considered and approved: (i) The appointment of M/s. K. S. Rao & Co., Chartered Accountants, Chennai ....
Others (Uncategorized) · 27 Mar 2026, 6:42 pm
Bafna Pharmaceuticals Appoints New Internal and Cost Auditors for FY27 Bafna Pharmaceuticals announced its Board of Directors, in a meeting on 27 Mar'26, approved key auditor appointments for FY27. The company appointed M/s. K. S. Rao & Co., Chartered Accountants, as its Internal Auditor. Additionally, M/s. N. Sivashankaran & Co., Cost Accountants, was appointed as the Cost Auditor. Both appointments are for a one-year term, effective from 01 Apr'26 to 31 Mar'27. These decisions are critical for the company's financial oversight and compliance framework for the upcoming fiscal year.
We hereby submit our response to the clarification sought by the Stock Exchange regarding the movement in the share price of the Company.
Others (Uncategorized) · 24 Mar 2026, 5:19 pm
Bafna Pharma Clarifies Share Price Movement to Exchanges Bafna Pharmaceuticals, in a filing dated 24 Mar'26, responded to an exchange query regarding significant share price movement. The company stated it is not aware of any specific information or event that would have a bearing on the price action. Management attributes the movement to general market conditions and investor sentiment, asserting no connection or control over the trading activity. The company also confirmed its ongoing compliance with SEBI's Regulation 30 disclosure requirements.
The Exchange has sought clarification from Bafna Pharmaceuticals Ltd on March 23, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 23 Mar 2026, 11:27 pm
The Board of Directors of the Company in their Meeting held on February 11, 2026 has inter-alia considered and approved the Un-Audited Financial Results of the Company along with the Limited ....
Financial Result · 11 Feb 2026, 11:14 pm
Bafna Pharma Q3FY26: Profit Up 93% YoY on Strong Revenue Growth Bafna Pharmaceuticals reported Q3FY26 results, showing a 92.7% YoY increase in profit to ₹183.69 lakhs. Revenue from operations grew 15.4% YoY to ₹3,828.58 lakhs. On a QoQ basis, revenue rose 7.9%, while profit declined 41.2% from ₹312.49 lakhs. For the nine months ended 31st Dec'25, profit surged 193.9% YoY to ₹835.06 lakhs. Basic EPS for the quarter was ₹0.78, up from ₹0.40 YoY but down from ₹1.32 QoQ. The auditors highlighted GST demands and pending foreign receivables as emphasis of matters.
The Board of Directors of the Company in the Meeting held on February 11, 2026 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited ....
Outcome · 11 Feb 2026, 11:06 pm
BAFNA PHARMACEUTICALS LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakhs) ■ Revenue: 3829 (+15.4% YoY | +7.9% QoQ) ■ EBITDA: 305 (-0.4% YoY | -28.8% QoQ) ■ EBITDA Margin (%): 8.0 (-126 bps YoY | -411 bps QoQ) ■ PAT: 184 (+93.8% YoY | -41.2% QoQ) ■ EPS (INR): 0.78 (+95.0% YoY | -40.9% QoQ)
Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve the Un-Audited Financial ....
Intimation · 11 Feb 2026, 5:30 am
Bafna Pharma Board Meeting on Feb 11, '26 to Approve Q3FY26 Results Bafna Pharmaceuticals has scheduled a Board of Directors meeting on Feb 11, '26, to consider and approve its Un-Audited Financial Results for the quarter ended Dec 31, '25. In connection with this, the trading window for designated persons will remain closed from Jan 01, '26, to Feb 13, '26, inclusive.
We hereby inform you that the Outlook of the Credit Ratings assigned to the Bank loan facilites of the Company has been revised by ICRA Limited.
Others (Uncategorized) · 24 Jan 2026, 12:32 am
Bafna Pharma Credit Rating Outlook Upgraded to Positive by ICRA ICRA revised its outlook on Bafna Pharmaceuticals' Rs. 50.00 crore bank loan facilities to Positive from Stable on 23rd Jan'26. The long-term rating was reaffirmed at [ICRA] BB+ (Positive). This applies to facilities including a Rs. 25.87 crore term loan and Rs. 20.00 crore in cash credit. The short-term rating for the Rs. 5.00 crore letter of credit was also reaffirmed at [ICRA] A4+. The upgrade reflects an improved credit profile and is a positive signal for the company's financial stability.
The Board of Directors of the Company in the Meeting held on November 11, 2025 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited ....
Financial Result · 11 Nov 2025, 11:02 pm
The Board of Directors of the Compant in the meeting held on November 11, 2025 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited ....
Outcome · 11 Nov 2025, 10:52 pm
Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2025 ,inter alia, to consider and approve the Un-Audited Financial ....
Intimation · 11 Nov 2025, 5:30 am